West Africa, where it was discovered [4] . To examine the occurrence of human hantavirus infections in this part of Guinea, known as Forest Guinea, we performed extensive investigations of serum collections by using a battery of serological hantavirus assays, which included a neutralization assay for SANGV.
Methods. A total of 717 serum samples from 2 cohorts of human subjects were included in the study. Approval for the investigation was obtained from the National Ethics Commission of Guinea, and all participants gave informed consent prior to enrollment.
In 2005, a retrospective study was performed that identified 68 patients originating from Sangassou, a rural village in the Macenta district of Forest Guinea, or its surroundings. Patient records in the regional hospital of Macenta were screened for patients with fever of unknown origin (FUO) and signs and symptoms suggestive of hantavirus disease or other viral hemorrhagic fever (fever, renal failure, respiratory failure, and bleeding) who had been hospitalized at any time during the preceding 12 months. The available clinical information was extracted from hospital records, and the patients were then visited in their homes, where blood was drawn. In selected cases, a second blood sample was collected after ∼1 year to monitor titers of immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies.
The present study included 649 serum samples from a Lassa fever survey performed in Forest Guinea in 2001. Twenty-nine villages with access by road in the districts of Gueckedou, Lola, and Yomou had been randomly chosen, and a modified cluster sampling approach was used to enroll minimally 20 participants from each village.
All human serum samples were tested for IgG antibodies against Puumala virus, Dobrava virus, and SANGV by enzymelinked immunosorbent assay (ELISA) and IFA, and for IgM antibodies by ELISA, according to published protocols [5, 6] . For IFA, infected cells and uninfected cells were mixed in a ratio of 1:3 to ensure specificity of the readouts. ELISAs were performed using the recombinant nucleocapsid proteins of the respective virus types, as described elsewhere [6] . Reciprocal titers of у400 by ELISA and of у16 by IFA were considered positive results. Serum samples were also tested using a commercially available Western blot kit (recomBlot; Mikrogen) based on antigens of Puumala virus, Dobrava virus, Hantaan virus, and Seoul virus and a commercial IFA kit (Hantavirus Mosaic 2; Euroimmun) based on antigens of Hantaan virus, Puumala virus, Seoul virus, Saaremaa virus, Dobrava virus, and Sin Nombre virus, according to the manufacturers' instruc- tions. Infectious focus reduction neutralization tests (FRNTs) were performed with viable Puumala virus, SANGV, Hantaan virus, and Seoul virus under biosafety level 3 conditions [7] . To determine possible nonspecific reactions in the FRNT, 7 serum samples from the Sangassou patient cohort with negative ELISA results were tested at various dilutions starting at 1:20 with Hantaan virus, Seoul virus, SANGV, and Dobrava virus. Because none of the serum samples showed neutralizing activity at this dilution, it was defined as the cutoff for this assay. Lassa virus antibodies were detected by indirect IFA as previously described, using a titer of у20 as the cutoff [8] .
Initially, all serum samples were screened by ELISA for hantavirus IgG and IgM using 3 different antigens (Puumala virus, Dobrava virus, and SANGV) in separate assays. Positive results were confirmed by Western blot analysis and then subjected to IFA and FRNT, in which reciprocal titers of 16 and 20, respectively, were considered positive results. Finally, serum samples with positive ELISA results scored positive if they were confirmed by Western blot analysis as well as by IFA and/or FRNT.
Results. Table 1 shows the reactivity of the serum samples that were confirmed positive in the respective serological assays. In the population sample of Forest Guinea, 8 (1.2%) of 649 persons were found to be positive for hantavirus antibodies, and in 6 of these 8 persons, hantavirus neutralizing antibodies were detected with reciprocal titers of 40-160 (Table 1) . Two persons were found to have SANGV-neutralizing antibodies. The prevalence in the population of Lassa virus antibodies detected by IFA was 13.6% (data not shown).
In patients with FUO from Sangassou village, Forest Guinea, hantavirus IgG antibodies were retrospectively detected in 3 (4.4%) of 68 persons. From 1 of these seropositive patients, an 8-year-old boy (patient S55), paired serum samples could be obtained. The patient had experienced typical HFRS symptoms, such as fever, chills, headache, asthenia, myalgia, breathing difficulty, nausea, vomiting, oliguria, hypotonia, and edema of the face and lower extremities. The duration of the illness was recorded as 1 week. The serum sample obtained after the acute phase of illness showed titers of IgM against SANGV that were 4-fold greater than those against Puumala virus ( Table 2) . A sample taken 1 year later was found to be IgM negative and exhibited a reciprocal neutralizing antibody titer of 80 only against SANGV (Tables 1 and 2 ). The other 2 clearly seropositive patients (patient S57, an 11-year-old girl; and patient S60, a 9-year-old girl) experienced similar symptoms but not oliguria or facial edema. However, epistaxis was recorded for patient S60 during the course of the disease (Table 1) .
Discussion. In Africa, the first serological indications of human hantavirus infections were obtained in the early 1980s, when Gonzalez et al [2] detected hantavirus antibodies in persons in Benin, Burkino Faso, Central African Republic, and Gabon, with seroprevalence rates of 0%-14%. Other serological surveys have reported human hantavirus infections also in Senegal, Nigeria, and Egypt [9] [10] [11] . These studies were conducted using only 1 assay, IFA, which is intrinsically limited by specificity problems. Therefore, the detection of unequivocally hantavirus-positive serum requires a combination of screening and confirmatory assays [1, 5, 6] . To type the hantavirus-specific antibodies, the FRNT is considered as a gold standard that is able to discriminate between different species of hantaviruses [5, 7] . To our knowledge, we report here the most extensive and detailed characterization of human sera from Africa, utilizing all available assays for screening, confirmation, and typing of hantavirus genus-and type-specific IgM and IgG antibody responses.
In our previous study [4] , the presence of an indigenous hantavirus, named Sangassou virus (SANGV), was revealed in Forest Guinea by extensive screening of 11000 rodents that belonged mainly to the genus Mastomys. This novel virus of unknown pathogenicity was shown to be most closely related to the Dobrava virus clade of hantaviruses, whose members cause the most severe cases of HFRS in Europe [1] .
Specific hantavirus antibodies were detected in a populationbased sample of patients in Forest Guinea (1.2% positivity) and in patients with FUO who originated from Sangassou, Forest Guinea (4.4% positivity), with cases of SANGV-neutralizing antibodies being present in both cohorts. This finding constitutes, to our knowledge, the first report of hantavirus-neu-tralizing antibodies in serum in Africa, confirming and extending the previous preliminary evidence of human hantavirus infection on this continent.
In addition, the detection of SANGV-specific IgM and neutralizing antibodies in paired serum samples from a patient with signs and symptoms consistent with pediatric HFRS [12, 13] argues strongly for a pathogenicity of SANGV or a related African hantavirus. It is interesting to note that the 2 other hantavirus-seropositive FUO patients from Sangassou village were children too. Prospective studies are needed to amplify and characterize viral nucleic acid sequences from hantavirusinfected patients as the final proof of which particular hantavirus(es) cause(s) HFRS in Guinea.
The 1.2% prevalence of hantavirus antibodies in the population sample from Forest Guinea is lower than the prevalences in some other West African countries that have been reported elsewhere [2, 9, 10] . Most likely this is because of the low specificity of the IFA used in these previous studies.
Lassa virus is endemic in Forest Guinea, with a human seroprevalence of about 15% in the general population [8] . In the 649 serum samples obtained in the present populationbased study, the serological (IFA) prevalence of Lassa virus infection of 13.6% contrasts with the rather low hantavirus antibody prevalence of 1.2%. Lassa virus is transmitted by its rodent reservoir, Mastomys natalensis, which is the most abundant domestic and peridomestic rodent genus in this ecosystem [14] . Because we detected hantaviruses only in the tree-living rodent species Hylomyscus simus and in shrews (Crocidura theresae), but not in Mastomys species or in other rats or mice [4, 15] , we conclude that hantaviruses are probably not transmitted (peri)domestically in villages of Forest Guinea.
The Guinean forests of West Africa extend from Guinea and Sierra Leone eastward to Cameroon, forming the so-called Upper Guinean forest block. Our detection of a considerable prevalence of specific hantavirus antibodies in the general population of Forest Guinea and the evidence of hantavirus disease in humans exhibit the first (to our knowledge) conclusive proof that hantaviruses are able to infect humans and cause disease in Africa. Hantavirus infections may be a significant unrecognized medical problem in Guinea and other parts of West Africa.
